- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.09. | Cibus, Inc.: Cibus and Crystal Crop Protection Team Up to Improve India's Mustard Crop | 2 | GlobeNewswire (USA) | ||
| 14.08. | Cibus updates Latin America rice launch to 2028 while outlining $20M-$40M biofragrance revenue opportunity | 1 | Seeking Alpha | ||
| CIBUS Aktie jetzt für 0€ handeln | |||||
| 13.08. | Earnings Call: Cibus verfehlt Umsatzprognose für Q2 2026 - Aktie bricht nachbörslich um 16 % ein | 1 | Investing.com Deutsch | ||
| 13.08. | Transcript: Cibus Q2 2026 Earnings Conference Call | 1 | Benzinga.com | ||
| 13.08. | Cibus GAAP EPS of -$0.29 misses by $0.10, revenue of $0.99M misses by $0.71M | 1 | Seeking Alpha | ||
| 13.08. | Cibus, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.08. | Cibus, Inc.: Cibus Reports Second Quarter Financial Results and Provides Business Update | 267 | GlobeNewswire (Europe) | Commercialization execution advances in Rice and Sustainable Ingredients United States and European Union now aligned on generally treating crops with no added foreign DNA as conventionally bred Quarterly... ► Artikel lesen | |
| 11.08. | Lendlease sells half stake in two regional shopping centres to Cbus | - | Inside Retail | ||
| 14.07. | Cibus (CBUS) Welcomes Landmark EU Crop Breeding Decision | - | Insider Monkey | ||
| 23.06. | Cibus, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 17.06. | Cibus, Inc.: Europe Recognizes Nature-Based Plant Improvement, Opening a New Pathway for Cibus | 1 | GlobeNewswire (USA) | ||
| 09.06. | Cibus names board member Craig Wichner as new CEO | 1 | Seeking Alpha | ||
| 09.06. | Cibus appoints Craig Wichner as chief executive officer | 3 | Investing.com | ||
| 09.06. | Cibus, Inc.: Cibus Names Agricultural Biotechnology Leader Craig Wichner as Chief Executive Officer to Accelerate Growth and Value Creation | 289 | GlobeNewswire (Europe) | SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the "Company" or "Cibus"), a leading agricultural technology company that develops and licenses plant traits to seed companies... ► Artikel lesen | |
| 05.06. | Cibus, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.05. | Cibus outlines runway into late Q1 2027 while shifting U.S. rice launch to 2029 | 3 | Seeking Alpha | ||
| 14.05. | Cibus Q1 2026: Deutlich geringerer Verlust und verbesserte Kosteneffizienz | 1 | Investing.com Deutsch | ||
| 14.05. | Cibus Q1 2026 Earnings Call: Complete Transcript | 2 | Benzinga.com | ||
| 14.05. | Cibus, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 14.05. | Cibus GAAP EPS of -$0.33 misses by $0.06, revenue of $1.68M beats by $0.06M | 2 | Seeking Alpha |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 79,40 | -1,31 % | Evotec crasht, BioNTech wackelt: Warum die Biotech-Baisse ausgerechnet dieses Nischenfeld verschont | ||
| EVOTEC | 2,598 | +2,77 % | Evotec Aktie: Zwischen 3,50 und 10 Euro - wo liegt das Kursziel? | Die überraschend guten Quartalszahlen von Evotec stoßen bei Analysten auf ein geteiltes Echo. Während Deutsche Bank Research und Berenberg trotz der positiven Geschäftsentwicklung bei ihren neutralen... ► Artikel lesen | |
| MODERNA | 203,95 | -3,30 % | 3 Transportvehikel für die Präzisionsmedizin: Warum Moderna, uniQure und NurExone auf Lipide, Viren und Exosomen setzen | ||
| NOVAVAX | 10,720 | -6,29 % | Novavax: Neue Zulassungen - was Anleger jetzt prüfen | ||
| ILLUMINA | 238,85 | -0,15 % | $100 Invested In Illumina 15 Years Ago Would Be Worth This Much Today | ||
| PALATIN TECHNOLOGIES | 6,930 | +6,78 % | Palatin Technologies, Inc.: Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update | Programs are focused on rare obesity disorders associated with the melanocortin 4 receptor (MC4R) pathway, including hypothalamic obesity, Prader-Willi syndrome... ► Artikel lesen | |
| BRAIN BIOTECH | 2,750 | +3,38 % | BRANDMELDUNG bei BRAIN Biotech AG: Ist das der Beginn einer Kursexplosion? - Dringend handeln! | ||
| EDITAS MEDICINE | 2,160 | -0,46 % | Editas Medicine, Inc.: Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia | Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C lowering Company remains on track to begin patient dosing this year and report initial safety... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,210 | +0,39 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth | -Supports BioCryst's evolution toward a more disciplined R&D model centered on external innovation- RESEARCH TRIANGLE PARK, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:... ► Artikel lesen | |
| IBIO | 0,685 | -1,86 % | iBio, Inc. - 8-K, Current Report | ||
| TME PHARMA | 0,107 | 0,00 % | TME Pharma NV: TME Pharma CEO Message | TME PHARMA CEO MESSAGE Berlin, Germany, September 16, 2026, 8.00am CET - TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 0,910 | -1,97 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance | Critical Manufacturing Milestone Supports Supply Chain Readiness and Planned Phase 2b Clinical Trial Initiation in First Quarter 2027King of Prussia, Pennsylvania--(Newsfile Corp. - October 13, 2026)... ► Artikel lesen | |
| CELLECTIS | 1,046 | 0,00 % | XFRA ZVA: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| MACROGENICS | 2,980 | +1,36 % | MacroGenics doses first patient in MGC030 cancer trial | ||
| FERMENTALG | 0,400 | 0,00 % | FERMENTALG: Half-year results 2026: Strict financial discipline and a stronger cash position to enter the next growth cycle from the best possible position | Growth in DHA sales in high-value segments and start of production of the new EPA/DHA ΩRIGINS range;
First orders for the natural blue colorant Galdieria Blue, with volume deliveries expected... ► Artikel lesen |
CIBUS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,300 Euro und damit +0,78 % im Plus. Die Dividendendrendite beträgt aktuell +7,59 % (berechnet anhand der Ausschüttung von 0,10 Euro in den letzten 12 Monaten).
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CIBUS INC finden Sie auf Wallstreet Online.